Royalty portfolio
Innoviva owns royalty rights on respiratory medicines sold by GSK, including inhaled treatments for asthma and COPD. It does not make the drugs itself; it collects income tied to sales of those products.
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Innoviva is a healthcare royalty company. Its main business is owning rights to receive payments on medicines developed and sold by other companies, especially inhaled treatments for lung diseases. Instead of running a big drug sales force, Innoviva sits further up the value chain and collects income when partner products sell well.
The company makes money mainly through royalty payments and, in some cases, through milestones or other contractual payments tied to partnered drug programs. Its main economic customers are really the pharmaceutical partners that market these medicines, along with the patients and doctors who use the products they sell. Innoviva’s role is different from a typical drug maker because it usually does not manufacture or market the medicines itself; it owns a stream of cash flows from intellectual property and collaboration agreements.
This model gives Innoviva a business built around healthcare assets rather than a broad product portfolio. The key things that drive its results are the sales of the partnered therapies and the strength of the underlying patent and licensing agreements. For investors, that makes Innoviva easier to think of as a royalty and licensing business than as a traditional pharmaceutical company.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more